恩曲替尼
Tier C — Watch / tradeEntrectinib · all drugs expiring in 2030 →
Targets：Trk-C、Trk-A、Trk-B、ALK、ROS
Brand：罗圣全、Rozlytrek
Indications (approved)：实体瘤、非小细胞肺癌
Regional status
Synthetic routes & intermediates1 routes
Routes are ordered originator first, then optimised / process (non-patent) routes; each lists steps, overall yield and the intermediate table (code / CAS / name) — ready for supplier sourcing and RFQ. Rendered by this site from structured data; no third-party route graphics used.
| Code | CAS No. | Intermediate |
|---|---|---|
| ENTR-001 | 461-96-1Available | 1-bromo-3,5-difluorobenzene |
| ENTR-002 | 218301-22-5Available | 2-fluoro-5-formylbenzonitrile |
| ENTR-003 | 1108745-07-8Available | 5-((3,5-difluorophenyl)(hydroxy)methyl)-2-fluorobenzonitrile |
| ENTR-004 | 1108745-09-0Available | 5-(3,5-difluorobenzoyl)-2-fluorobenzonitrile |
| ENTR-005 | 1108745-11-4Available | (3-amino-1H-indazol-5-yl)(3,5-difluorophenyl)methanone |
| ENTR-006 | 1108745-14-7Available | N-(5-(3,5-difluorobenzoyl)-1H-indazol-3-yl)-2,2,2-trifluoroacetamide |
| ENTR-007 | 1108745-16-9Available | N-(5-(3,5-difluorobenzoyl)-1-trityl-1H-indazol-3-yl)-2,2,2-trifluoroacetamide |
| ENTR-008 | 1108745-18-1Available | (3-amino-1-trityl-1H-indazol-5-yl)(3,5-difluorophenyl)methanone |
| ENTR-009 | 942271-64-9Available | 4-(4-methylpiperazin-1-yl)-2-nitrobenzoic acid hydrochloride |
| ENTR-010 | 1108745-20-5Available | N-(5-(3,5-difluorobenzoyl)-1-trityl-1H-indazol-3-yl)-4-(4-methylpiperazin-1-yl)-2-nitrobenzamide |
| ENTR-011 | 1108745-22-7Available | N-(5-(3,5-difluorobenzoyl)-1H-indazol-3-yl)-4-(4-methylpiperazin-1-yl)-2-nitrobenzamide |
| ENTR-012 | 1108743-56-1Available | N-(5-(3,5-difluorobenzyl)-1H-indazol-3-yl)-4-(4-methylpiperazin-1-yl)-2-nitrobenzamide |
| ENTR-013 | 1108743-96-9Available | 2-amino-N-(5-(3,5-difluorobenzyl)-1H-indazol-3-yl)-4-(4-methylpiperazin-1-yl)benzamide |
| ENTR-014 | 29943-42-8Available | tetrahydro-4H-pyran-4-one |
Frequently asked questions
What are the approved indications of Entrectinib?
Approved indications include: 实体瘤, 非小细胞肺癌.
When does the Entrectinib patent expire?
Based on public sources, the Entrectinib patent expires in 2030.
How many synthesis routes are recorded for Entrectinib?
1 synthesis routes are recorded; the shortest is 11 steps with 1.61 g total yield. Intermediates in each route carry codes and CAS numbers.
Where can I buy Entrectinib intermediates?
14 intermediate CAS of Entrectinib are available through the Unibest supply network — see the route tables on this page and request a quote per CAS.
How do I get a quote for Entrectinib intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-24